Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma, Others), By Product (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Site (Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach, Others), By End User (Hospitals, Clinics, Others), By Region, & Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 2.71 Billion
CAGR (2026-2031)	6.12%
Fastest Growing Segment	Carcinoid Tumors
Largest Market	North America
Market Size (2031)	USD 3.87 Billion

Market Overview

The Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 2.71 Billion in 2025 to USD 3.87 Billion by 2031 at a 6.12% CAGR. The global neuroendocrine tumor (NET) treatment market encompasses therapeutic solutions designed to manage a diverse group of rare and complex tumors originating from neuroendocrine cells throughout the body, with treatments aimed at controlling tumor progression, managing hormone-related symptoms, and improving patient outcomes. The market's expansion is fundamentally driven by the increasing incidence and prevalence of NETs, alongside significant advancements in diagnostic techniques such as gallium-68 DOTATATE PET/CT, which facilitate earlier and more accurate detection. Furthermore, the ongoing development and adoption of novel targeted therapies and radiopharmaceuticals, including peptide receptor radionuclide therapy (PRRT), contribute substantially to market growth by offering improved treatment efficacy and patient survival.

According to the American Society of Clinical Oncology, more than 12,000 individuals in the United States are diagnosed with a neuroendocrine tumor each year. A significant challenge impeding market expansion, however, is the inherent heterogeneity of neuroendocrine tumors, which often leads to diagnostic delays and complexities in developing universally effective therapeutic strategies for all subtypes.

Key Market Drivers

Rising Incidence and Treatment Demand
The global neuroendocrine tumor treatment market is significantly propelled by the rising incidence and prevalence of these rare yet complex malignancies. An increasing number of individuals are being diagnosed, necessitating a greater demand for effective therapeutic interventions. This growing patient population directly expands the market for various treatments, from surgical options to advanced pharmaceutical therapies. According to the HealthWell Foundation, in April 2025, neuroendocrine tumor diagnoses were increasing by more than 5 percent annually, highlighting the persistent growth in the patient pool. This demographic shift underscores the ongoing need for continuous development and broader accessibility of treatment solutions.

Advancements in Diagnostics and Theranostics
Complementing the rising disease burden, advancements in diagnostic technologies further drive market expansion by enabling earlier and more accurate detection of neuroendocrine tumors. Improved diagnostic tools facilitate timely intervention, leading to better patient outcomes and increased utilization of treatment modalities. This includes innovations in theranostic agents which combine diagnostic imaging with targeted therapy. For instance, according to ITM Isotope Technologies Munich SE and the Institut Laue-Langevin, in June 2025, ITM secured priority access to half of ILL's neutron irradiation capacity for the production of non-carrier-added Lutetium-177, a critical medical radioisotope used for radiopharmaceutical therapies, thereby enhancing capabilities in both diagnosis and treatment. Furthermore, the overall market is bolstered by strategic investments; according to The Economic Times, in May 2026, Zydus Lifesciences announced an agreement to acquire US-based pharma company Assertio Holdings for $166.40 million to build a specialty oncology business in the US, with a focus on rare disease segments.

Download Free Sample Report

Key Market Challenges

The inherent heterogeneity of neuroendocrine tumors (NETs) presents a significant challenge to the expansion of the global neuroendocrine tumor treatment market. This fundamental variability in tumor origin, biological behavior, and clinical presentation across different NET subtypes leads to considerable diagnostic complexities. Patients often experience prolonged periods of non-specific symptoms, which can delay accurate identification of the disease. According to the Journal of Oncology Practice in November 2025, diagnostic delay for neuroendocrine tumors approaches five years both within the United States and globally, directly impacting patient outcomes and the timely initiation of effective therapies.

This inherent diversity further complicates the development of broadly applicable therapeutic solutions. Treatment approaches effective for one NET subtype may demonstrate limited efficacy or safety for others, requiring a fragmented research and development landscape focused on highly specialized agents. Such a landscape increases the complexity and cost associated with drug development, thereby restraining the pace at which novel, effective treatments can be introduced to the market and ultimately impeding overall market growth.

Key Market Trends

The growing adoption of personalized medicine and targeted therapies represents a significant trend in the global neuroendocrine tumor treatment market, emphasizing tailored treatment approaches based on specific tumor characteristics and patient profiles. This shift moves beyond conventional broad-spectrum treatments, focusing on molecular pathways to improve efficacy and minimize adverse effects. The increasing number of clinical trials for these specialized therapies underscores this trend. According to NETRF, in March 2026, in the 'NETRF Clinical Trial Roundup: March 2026' report, updated findings from the Phase 3 COMPETE trial showed that participants treated with the investigational radiopharmaceutical therapy ITM-11 for pancreatic neuroendocrine tumors experienced a median progression-free survival of 24.5 months, compared with 14.7 months for those receiving everolimus. This highlights the potential of precision approaches to significantly enhance patient outcomes.

The integration of artificial intelligence (AI) in diagnostics and treatment planning is another pivotal trend transforming the neuroendocrine tumor treatment landscape by enhancing accuracy and efficiency. AI applications are improving the interpretation of complex imaging and pathological data, enabling earlier and more precise identification of tumors and facilitating the development of individualized treatment strategies. This technological advancement supports clinicians in making informed decisions by leveraging vast datasets. According to The ASCO Post, in July 2025, in the 'Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers' article, researchers developed an AI-powered online platform where models achieved a diagnostic accuracy of 99% or more in recognizing multiple endocrine tumors. Such high diagnostic accuracy can lead to timely interventions and optimized patient management in this complex disease area.

Segmental Insights

The Carcinoid Tumors segment is the fastest-growing within the Global Neuroendocrine Tumor Treatment Market. This rapid expansion is primarily driven by the increasing incidence and growing awareness of carcinoid tumors, leading to earlier and more accurate diagnoses. Furthermore, advancements in treatment methodologies, including the development of innovative therapies like somatostatin analogs and targeted treatments, have significantly improved patient management. Enhanced diagnostic technologies, such as automated testing, also play a crucial role in boosting demand for specialized carcinoid tumor interventions, reinforcing its leading growth trajectory in the market.

Regional Insights

North America leads the global neuroendocrine tumor treatment market, primarily due to its robust healthcare infrastructure and high healthcare expenditure. The region benefits from a strong research environment, fostering the development and rapid adoption of innovative treatment options. Advanced diagnostic capabilities and a heightened awareness among healthcare professionals and patients contribute significantly to early detection and treatment initiation. The presence of major pharmaceutical companies and supportive government investments in oncology research further reinforce North America's dominant position.

Recent Developments

• In February 2026, Novartis announced plans for the construction of a new radioligand therapy (RLT) production facility in Denton, Texas. This strategic initiative marks the fifth such manufacturing site for Novartis in the U.S. and aims to augment the company’s network capacity for its radiopharmaceutical treatments, including Lutathera, which is approved for neuroendocrine tumors. This expansion is designed to address the increasing demand for RLTs and to ensure a more robust and timely supply of these advanced therapies to patients, particularly in the southern U.S.
• In December 2025, Crinetics Pharmaceuticals, Inc. initiated its Phase 1/2 BRAVESST2 study, with the first patient dosed. This trial is evaluating CRN09682, a nonpeptide drug conjugate designed to target somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. This development represents an advancement in precision oncology within the neuroendocrine tumor treatment market, focusing on delivering a potent cytotoxic payload directly to tumor cells to enhance treatment efficacy and potentially reduce systemic toxicities for patients.
• In March 2025, the U.S. Food and Drug Administration approved cabozantinib for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs). This approval, based on results from the Phase III CABINET trial, represented an important expansion of available systemic therapies for this patient population. Subsequently, in July 2025, Ipsen received European Commission approval for Cabometyx (cabozantinib) for the same indication. This collective regulatory success provided a new treatment option for patients with advanced NETs across major global markets.
• In January 2025, ITM Isotope Technologies Munich SE announced positive topline results from its Phase 3 COMPETE trial involving ITM-11 (n.c.a. ¹⁷⁷Lu-edotreotide), a targeted radiotherapeutic agent. The study demonstrated a statistically significant improvement in progression-free survival for patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared to everolimus. Further data presented in October 2025 confirmed a higher objective response rate. In March 2026, post-hoc subgroup analyses further detailed prolonged progression-free survival and higher objective response rates specifically in pancreatic neuroendocrine tumor patients.

Key Market Players

• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Hutchison MediPharma Limited.
• AVEO Pharmaceuticals, Inc.
• Ipsen Pharma.
• Eli Lilly and Company.
• Exelixis, Inc.
• Jubilant Pharmova Limited

By Type	By Product	By Site	By End User	By Region
Meningiomas Adrenal Cancer Carcinoid Tumors Paraganglioma Pheochromocytoma Others	Somatostatin Analogs (SSAs) Targeted Therapy Others	Lung Pancreas Colon Small Intestine Rectum Stomach Others	Hospitals Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Neuroendocrine Tumor Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neuroendocrine Tumor Treatment Market, By Type:

• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

• Neuroendocrine Tumor Treatment Market, By Product:

• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

• Neuroendocrine Tumor Treatment Market, By Site:

• Lung
• Pancreas
• Colon
• Small Intestine
• Rectum
• Stomach
• Others

• Neuroendocrine Tumor Treatment Market, By End User:

• Hospitals
• Clinics
• Others

• Neuroendocrine Tumor Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE